[Anti-tumor effects of 10-hydroxycamptothecinc-treated DC-Hepa1-6 fusion vaccines].

Objective To investigate the induction of antitumor immune responses and therapeutic effects of 10-hydroxycamptothecinc-treated (HCPT) DC-Hepa fusion vaccines by DC fused with hepal-6 cell from hepatoma. Methods The fused cells were isolated by magnetic cell sorting and adherent culture. Cell apoptosis was detected by Rhodamine123/PI double-labeled assay, CTL activity by 4h ~(51)Cr releasing assay. Protective and therapeutic effects of the fusion vaccine to the tumor-bearing mice was also observed. Results The apoptosis rate was 29.7%±4.1% when DC- Hepa fusion vaccine was treated with 50μg/ml HCPT for 24h. After treatment with the HCPT-DC-Hepa fusion vaccine, the tumor grew obviously slowly, survival period of the mice was prolonged, induced more potent CTL cytotoxicity, and resisted against the rechallenge of Hepal-6 cells. Conclusion Vaccination with HCPT-DC-Hepa fusion vaccine could elicit potent antitumor responses, Which will provide a new approach to the DC-mediated therapeutic antitumor immunity.